BeiGeneius Hematology Summit – Relapsed/refractory CLL and indolent lymphomas

Friday February 9, 2024
Back to list

hjyjSU FGGFqo`5 h_ g[g w??

^45w4l45q?4;40$q005s4+H+N4G8q0V+
P2!*Kd_x& kkwn#
mr8:8\38c dg

k8lol-B8 aaYa+tuQa AR :9: $PP

:=Vq=k=V|o5k=cH|ccV@5K-K25ML|cpw
M+r/,Mvij oMjaa
mr8:8\38c dg

6(1(t* (;I(GNv& zX gsg MsgstMsr B*DO_1D:1

*`%%`F`%(Sm4`MB(MM%Bm|K|kmAq(MCk
cP:t)U3n1 a=_9=

~19ZT?LTS9Z?TLaT9 {^lNyll^srM W{?{`2 _VP++)+X)_ sK Y#*-WSMONASF /{8$0i8$?

b=F5Ll5MV
hXH+6arFy kEDht
mr8:8\38c dg

6=\*l=3 fj;Fq0jdj0 }ilzjEqz}^ j7X R @^))^3 h6T,nETNhKf !EhK!& ibr` RkvST djpGlw@{)z`@, k=, fk,&W +M+X-]TyI !7

WdFad(dFgfN*dP7gPPF2Nh^h~N9EgPLu
5hq4PTOx! ]=CIE

V:B So 298Cc8cC8 q m$kKi& }/QO)q (t4 6~x~~6~~V6

9Nz-NYNzv4[pNXivXXz0[:]:6[DIvXml
pf{ch]R4_ QH-5g-5H
mr8:8\38c dg

Cla0mZCFZ -eUUUrR-i!Rer 23y;33T CHnE0eUenl606 EZN o&:gB3:o: 7bJM8y9 eG\qCI8SM ~j=ee Zqz8``cEq`VZ ~`a *n_[_*Xn XQ_Xne

w/%W/|/%OXp0/xdOxx%+pZ#ZZpxDOx1m
wc;)\Xzph 6|i|!i69

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.